Clinical reference Biomarker Directory
Back to directory

HP

Established

Haptoglobin helps distinguish hemolytic from non-hemolytic anemia by reflecting free hemoglobin clearance.

Also known as Haptoglobin
In plain language

Haptoglobin mops up free hemoglobin released when red blood cells break apart. Low levels are a good clue for hemolysis (red cell destruction), though inflammation elsewhere in the body can mask this by keeping haptoglobin falsely normal.

Biomarker & context

Haptoglobin is a liver-produced protein that binds free hemoglobin released during red blood cell breakdown, serving as a key marker for distinguishing hemolytic from non-hemolytic anemia.

What it indicates

Low haptoglobin alongside anemia points toward hemolysis (red cell destruction), since haptoglobin gets rapidly consumed and cleared when binding free hemoglobin; it is interpreted alongside LDH (elevated) and indirect bilirubin (elevated) as a hemolysis panel.

Diagnosis & clinical testing

Measured via serum immunoassay; haptoglobin is also an acute-phase reactant, so it can be falsely normal or elevated in a patient with both hemolysis and concurrent inflammation, a diagnostic trap worth recognizing.

Guiding treatment

Confirmed hemolysis prompts further workup for the underlying cause (autoimmune hemolytic anemia, mechanical heart valve, G6PD deficiency, hereditary spherocytosis, etc.), guiding specific treatment.

Clinical significance

Can be falsely normal in patients with concurrent inflammation, since it is also an acute-phase reactant.

References
  1. General hematology reference literature on the hemolysis workup (haptoglobin, LDH, bilirubin, reticulocyte count).